ATE308618T1 - Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen - Google Patents

Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen

Info

Publication number
ATE308618T1
ATE308618T1 AT99924978T AT99924978T ATE308618T1 AT E308618 T1 ATE308618 T1 AT E308618T1 AT 99924978 T AT99924978 T AT 99924978T AT 99924978 T AT99924978 T AT 99924978T AT E308618 T1 ATE308618 T1 AT E308618T1
Authority
AT
Austria
Prior art keywords
hcv
mimotopes
hypervariable region
glycoprotein
hvr1
Prior art date
Application number
AT99924978T
Other languages
English (en)
Inventor
Alfredo Nicosia
Armin Lahm
Anna Tramontano
Riccardo Cortese
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Application granted granted Critical
Publication of ATE308618T1 publication Critical patent/ATE308618T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT99924978T 1998-05-19 1999-05-14 Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen ATE308618T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9810756.8A GB9810756D0 (en) 1998-05-19 1998-05-19 Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof
PCT/EP1999/003344 WO1999060132A1 (en) 1998-05-19 1999-05-14 Mimotopes of hypervariable region 1 of the e2 glycoprotein of hcv and uses thereof

Publications (1)

Publication Number Publication Date
ATE308618T1 true ATE308618T1 (de) 2005-11-15

Family

ID=10832337

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99924978T ATE308618T1 (de) 1998-05-19 1999-05-14 Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen

Country Status (13)

Country Link
US (1) US7034108B1 (de)
EP (1) EP1002092B1 (de)
JP (1) JP4593780B2 (de)
KR (1) KR20010022026A (de)
CN (1) CN1274387A (de)
AT (1) ATE308618T1 (de)
AU (1) AU766610B2 (de)
CA (1) CA2297408C (de)
DE (1) DE69928064T2 (de)
DK (1) DK1002092T3 (de)
ES (1) ES2251832T3 (de)
GB (1) GB9810756D0 (de)
WO (1) WO1999060132A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2809402A1 (fr) * 2000-05-26 2001-11-30 Dev Des Antigenes Combinatoire Bibliotheques peptidiques combinatoires convergentes et leur application a la vaccination contre le virus de l'hepatite c
CA2409287A1 (en) * 2000-06-02 2001-12-13 Merck & Co., Inc. Hepatitis c virus conjugates
AU2002222139A1 (en) * 2000-12-09 2002-06-18 Cambridge University Technical Services Limited Hcv vaccines
ES2344253T3 (es) 2001-10-11 2010-08-23 MERCK SHARP & DOHME CORP. Vacuna contra el virus de la hepatitis c.
JP4475561B2 (ja) 2001-10-11 2010-06-09 メルク・シャープ・エンド・ドーム・コーポレイション C型肝炎ウイルスワクチン
CN1305898C (zh) * 2003-08-22 2007-03-21 中国科学院上海生命科学研究院 丙型肝炎病毒被膜蛋白hvr1模拟多肽、其编码基因及用途
CA2610919C (en) 2005-06-17 2013-09-10 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Hepatitis c virus nucleic acid vaccine
EP2030628B1 (de) * 2006-06-01 2012-08-15 Yun Cheng Peptid zur prophylaxe oder therapie von leberschäden sowie ein derivat davon und seine verwendung
US20070294785A1 (en) * 2006-06-13 2007-12-20 Athenix Corporation Methods for generating genetic diversity by permutational mutagenesis
CN101600800B (zh) 2006-11-29 2013-08-28 埃塞尼克斯公司 改良的grg23 epsp合酶:组合物和使用方法
CN110078800B (zh) * 2019-04-24 2021-01-29 中国人民解放军第二军医大学 合成肽在制备防治肝炎病毒感染药物中的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2118066T3 (es) 1989-10-05 1998-09-16 Optein Inc Sintesis y aislamiento, exentos de celulas, de nuevos genes y polipeptidos.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
IT1270939B (it) 1993-05-11 1997-05-26 Angeletti P Ist Richerche Bio Procedimento per la preparazione di immunogeni e reagenti diagnostici,e immunogeni e reagenti diagnostici cosi' ottenibili.
EP0697888B1 (de) * 1993-05-12 2003-09-17 Chiron Corporation Konserviertes Motiv der Hepatitis C Virus E2/NS1 Region
WO1995011922A1 (en) 1993-10-29 1995-05-04 Affymax Technologies N.V. In vitro peptide and antibody display libraries
US5492807A (en) 1993-11-19 1996-02-20 Santi; Daniel V. Method of obtaining diagnostic reagents, assays and therapeutics based on clinical manifestations of a disease
US6110465A (en) * 1995-06-07 2000-08-29 The United States Of America As Represented By The Department Of Health And Human Services Nucleotide and deduced amino acid sequences of hypervariable region 1 of the envelope 2 gene of isolates of hepatitis C virus and the use of reagents derived from these hypervariable sequences in diagnostic methods and vaccines
JPH11124398A (ja) * 1997-10-22 1999-05-11 Japan Energy Corp C型肝炎ウイルス由来の抗原ペプチドとそれを用いる抗体検査薬

Also Published As

Publication number Publication date
KR20010022026A (ko) 2001-03-15
GB9810756D0 (en) 1998-07-15
DE69928064T2 (de) 2006-07-20
CA2297408C (en) 2011-06-21
DE69928064D1 (de) 2005-12-08
CN1274387A (zh) 2000-11-22
JP4593780B2 (ja) 2010-12-08
WO1999060132A1 (en) 1999-11-25
US7034108B1 (en) 2006-04-25
AU766610B2 (en) 2003-10-16
EP1002092A1 (de) 2000-05-24
ES2251832T3 (es) 2006-05-01
EP1002092B1 (de) 2005-11-02
DK1002092T3 (da) 2006-03-06
JP2002515249A (ja) 2002-05-28
CA2297408A1 (en) 1999-11-25
AU4143599A (en) 1999-12-06

Similar Documents

Publication Publication Date Title
NO934542L (no) Hepatitt C virus (HCV) polypeptider
DE69232906T2 (de) Detektion des Hepatis-C Virus.
DK0754704T3 (da) Syntetiske antigener til påvisning af antistoffer mod hepatitis c-virus
NZ219113A (en) Hiv peptide containing epitope of the env protein
NZ237666A (en) Hiv envelope (env) polypeptides, antibodies and compositions for treating aids
NZ518999A (en) Vaccine compositions
DE69928064D1 (de) Mimotopen der hypervariabele region des e2 glykoproteins von hcv und deren verwendungen
ATE382696T1 (de) Immunoreaktive antigene des hepatitis e viruses
MY116208A (en) Improved hcv diagnostic agents
WO2001093804A3 (en) Hepatitis c virus conjugates
ATE320266T1 (de) Induktion von antigen-spezifischen t-zellen durch interferon
EP0600000A4 (de) Hepatitis c-nachweistest unter benutzung rekombinanter antigene der ns5-region.
CA2141670A1 (en) Peptides, analogues and mixtures thereof for detecting and eliciting antibodies to the e1 and e2 protein of rubella virus
IT1270941B (it) Peptidi di hcv e loro usi.
DE69921589D1 (de) Peptide zum Nachweis von HIV-1-Guppe O
SG145521A1 (en) Synthetic antigens for the detection of antibodies to hepatitis c virus

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1002092

Country of ref document: EP